文献速递免疫规划

全液体MenACWY-CRM结合疫苗的免疫原性与安全性研究

A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study.
PubMed 文献 · Vaccine · 2021-10-09

本研究为多中心随机对照观察者盲法2b期试验,979名健康成人接种单剂全液体或已上市MenACWY-CRM疫苗。结果显示全液体组对MenA的hSBA GMT非劣效于已上市疫苗,两组免疫原性、反应原性和安全性相似。

要点

  • 全液体MenACWY-CRM对MenA的免疫应答非劣效于已上市疫苗。
  • 两组疫苗耐受性良好,未发生与接种相关的严重不良事件。
  • MenA游离多糖和O-乙酰化水平变化未影响全液体疫苗免疫原性。

核心结论

  • 全液体MenACWY-CRM对MenA的免疫原性非劣效于已上市疫苗,且安全性和反应原性相似。
  • MenA游离多糖生成约30%和O-乙酰化降低约40%未影响全液体疫苗的免疫原性。

研究设计与样本

  • 多中心、随机、对照、观察者盲法2b期研究,纳入979名健康成人。
  • 受试者接种单剂全液体MenACWY-CRM或已上市MenACWY-CRM疫苗。

主要发现

  • MenA调整后hSBA GMT全液体组为185.16,已上市疫苗组为211.33。
  • MenA组间hSBA GMT比值为0.88,双侧95%CI下限为0.64,高于预设非劣效界值0.5。
  • 两组对每个血清群的免疫应答相似,且全液体组对MenA非劣效。
  • 两疫苗均耐受良好,无与接种相关的严重不良事件。

临床怎么用

  • 全液体单瓶 presentation 可简化接种操作,且免疫原性与安全性非劣效于已上市疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The currently licensed quadrivalent MenACWY-CRM conjugate vaccine presentation consists of two vials (lyophilised MenA and liquid MenCWY) to be reconstituted before injection. A new fully liquid formulation in a single vial has been developed to further improve the vaccine presentation. Since the MenA structure is subject to hydrolytic degradation, this study was conducted to compare the immunogenicity and safety of the investigational MenACWY-CRM liquid vaccine with the licensed vaccine. METHODS: In this multicentre, randomised, controlled, observer-blind, phase 2b study, 979 healthy adults were administered a single dose of MenACWY-CRM liquid presentation or the currently licensed MenACWY-CRM vaccine. MenA free saccharide generation was accelerated to approximately 30% in the liquid presentation and MenA polysaccharide O-acetylation was reduced to approximately 40%, according to a controlled procedure. Immunological non-inferiority of the MenACWY-CRM liquid to the licensed vaccine, as measured by human serum bactericidal assay (hSBA) geometric mean titres (GMTs) against MenA 1 month post-vaccination, was the primary study objective. Safety assessment was among the secondary objectives. RESULTS: Immune responses against each serogroup were similar between the two vaccine groups and was non-inferior for MenA. Adjusted hSBA GMTs for MenA were 185.16 and 211.33 for the MenACWY-CRM liquid presentation and currently licensed vaccine presentation, respectively. The between-group ratio of hSBA GMTs for MenA was 0.88, with a two-sided 95% confidence interval lower limit of 0.64, greater than the prespecified non-inferiority margin of 0.5, thus meeting the primary study objective. Both vaccines were well tolerated. No serious adverse events were considered related to vaccination. CONCLUSIONS: The levels of MenA free saccharide and polysaccharide O-acetylation did not affect the immunogenicity of the fully liquid presentation, which was demonstrated to be non-inferior to the immunogenicity of the currently licensed MenACWY-CRM vaccine against MenA. The immunogenicity, reactogenicity and safety profiles of the two vaccine presentations were similar.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vandermeulen C, Leroux-Roels I, Vandeleur J, et al. A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study. Vaccine. 2021. PMID: 34635373. doi:10.1016/j.vaccine.2021.09.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。